Back to mobile site

Citizens Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX) Ahead of Ph1 Results

September 17, 2026 4:10 AM EDT Send to a Friend
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login